Matteo Barbato

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Environmental endocrine disruptors in cardio-oncology: emerging modifiers of cardiovascular vulnerability in patients with cancer.

Environmental endocrine disruptors in cardio-oncology: emerging modifiers of cardiovascular vulnerability in patients with cancer.

Journal: Cardio-oncology (London, England)

Published: June 03, 2026

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.

Journal: International journal of molecular sciences

Published: March 12, 2026

Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk.

Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk.

Journal: Journal of translational medicine

Published: January 19, 2026

Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer.

Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer.

Journal: Journal of cardiovascular pharmacology

Published: October 06, 2025

Healthcare Management in Cardio-Oncology, Clinical Strategies and Future Perspectives: A Narrative Review.

Healthcare Management in Cardio-Oncology, Clinical Strategies and Future Perspectives: A Narrative Review.

Journal: Healthcare (Basel, Switzerland)

Published: September 15, 2025

Time to Combinatorial Regimens: SGLT2i and PCSK9i in High-Risk Cardio-Oncology Patients.

Time to Combinatorial Regimens: SGLT2i and PCSK9i in High-Risk Cardio-Oncology Patients.

Journal: Journal of cardiovascular pharmacology

Published: July 14, 2025

PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition.

PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition.

Journal: International journal of molecular sciences

Published: June 12, 2025

Cardio-Renal and Systemic Effects of SGLT2i Dapagliflozin on Short-Term Anthracycline and HER-2-Blocking Agent Therapy-Induced Cardiotoxicity.

Cardio-Renal and Systemic Effects of SGLT2i Dapagliflozin on Short-Term Anthracycline and HER-2-Blocking Agent Therapy-Induced Cardiotoxicity.

Journal: Antioxidants (Basel, Switzerland)

Published: April 03, 2025

In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy.

In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy.

Journal: Cancers

Published: February 21, 2025

Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients.

Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients.

Journal: International journal of molecular sciences

Published: September 06, 2024

The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients.

The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients.

Journal: Cancers

Published: February 13, 2024

YAP contributes to DNA methylation remodeling upon mouse embryonic stem cell differentiation.

YAP contributes to DNA methylation remodeling upon mouse embryonic stem cell differentiation.

Journal: The Journal of biological chemistry

Published: September 03, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026